Neumora Therapeutics Shares Plummet 80% After Drug Trial Failure
Neumora Therapeutics stock plummets 80% to $2.05 after pivotal Phase 3 trial of their depression drug fails, impacting investor confidence.
Topic
Phase 3 Trial Failure
A collection of 1 issue